S-1: Calidi Biotherapeutics Announces Common Stock and Warrant Offering

Calidi Biotherapeutics plans to offer common stock, pre-funded warrants, and common stock purchase warrants in a best efforts offering.

Summary

• Calidi Biotherapeutics intends to sell shares of its common stock along with Series A and Series B warrants.
• Pre-funded warrants may be offered in lieu of common stock to purchasers exceeding a beneficial ownership threshold.
• The offering is on a reasonable best efforts basis with Ladenburg Thalmann & Co. Inc. as the placement agent.
• The offering will terminate on February 15, 2024, unless terminated earlier.
• The company will pay the placement agent a cash fee of 8% of the gross proceeds, a management fee of 1% of the gross proceeds, and reimburse certain expenses up to $125,000.
• Placement agent warrants to purchase 5% of the number of shares of common stock offered will also be issued.
• There is no minimum offering amount required as a condition to closing.

Sentiment

Score: 6

Explanation: The document is neutral. It describes the terms of a financial offering, without expressing strong positive or negative sentiment. The risks are clearly outlined, but the offering itself is a standard business practice.

Positives

• The company has the flexibility to use proceeds for working capital and general corporate purposes.
• The offering provides an opportunity to raise capital to fund pre-clinical and clinical trials.

Negatives

• The offering is on a best efforts basis, so there is no guarantee of raising the full amount.
• New investors will experience immediate and substantial dilution.
• The company has broad discretion in the use of proceeds and may not use them effectively.
• The market price of the common stock may be volatile.

Risks

• The company may not sell all the securities offered, reducing the amount of proceeds received.
• Investors could be in a position where they have invested in our company, but we are unable to fulfill all of our contemplated objectives due to a lack of interest in this offering.
• The company may be unable to fulfill all of its contemplated objectives due to a lack of interest in this offering.
• The company may be unable to use such funds to effectively implement our business plan.
• The company may not be able to effectively implement our business plan.
• The company may not be able to effectively implement our business plan due to a lack of interest in this offering.

Future Outlook

The company intends to use the net proceeds from this offering for working capital and general corporate purposes, and pre-clinical and clinical trials subject to the actual amount of proceeds received.

Industry Context

This offering is typical for a clinical-stage biopharmaceutical company seeking to raise capital to fund its research and development activities.

Stakeholder Impact

• Shareholders will experience dilution.
• The company will have additional capital to fund its operations.
• The company's ability to execute its business plan will be enhanced.

Next Steps

• The company will proceed with the offering, seeking to secure commitments from investors.
• The company will file the final prospectus with the SEC.
• The company will close the offering and receive the net proceeds.

Key Dates

Keywords

common stock, warrants, offering, pre-funded warrants, placement agent, Calidi Biotherapeutics, securities